Weekly Report: what happened at FXH last week (0415-0419)?

Weekly Market Pulse: Are Higher Interest Rates Good For The Economy?

Interest rates surged last week on the back of a hotter-than-expected inflation report. The rise in rates last week pushed the 10-year to its highest level since the peak at 5% in October of last year. Gold has been setting new highs, trading above $2400.

Weekly Report: what happened at FXH last week (0408-0412)?

Drug shortages in U.S. at highest level on record since 2001

Healthcare Drug shortages in U.S. At highest level on record since 2001 since 2001. Shortages are largely caused by supply chain disruptions due to natural disasters and manufacturing quality issues. 323 medications in short supply in Q1 2024, the highest on record for the American Society of Health-System Pharmacists.

Weekly Report: what happened at FXH last week (0401-0405)?

Analysts Anticipate FXH Will Reach $123

First Trust Health Care AlphaDEX® ETF: Statement of changes in beneficial ownership of securities

Weekly Report: what happened at FXH last week (0325-0329)?

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

First Trust Health Care AlphaDEX Fund declares quarterly distribution of $0.1062

First Trust Health Care AlphaDEX® Fund ETF declares $0.1062 dividend

First Trust Health Care AlphaDEX® Fund ETF (FXH) declares $0.1062/share quarterly dividend. Payable March 28; for shareholders of record March 22; ex-div March 21. First Trust Health care AlphaDex® FundETF (FXh) is an exchange-traded fund.

Weekly Report: what happened at FXH last week (0318-0322)?

Taking Stock: Q2 2024 Equity Market Outlook

Implied FXH Analyst Target Price: $122

Weekly Report: what happened at FXH last week (0311-0315)?

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

2024 Outlook: A New 'Super Boom'? Or Chop And Churn?

Add Up The Parts: FXH Could Be Worth $122

Weekly Report: what happened at FXH last week (0304-0308)?

Why Biotech Stocks May Be Ready For A Recovery

Biotech stocks have struggled in recent quarters as high interest rates take a toll on the capital-intensive sector. Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with MoneyTalk's Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a recovery.